# Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT04781374** · PHASE2 · WITHDRAWN · sponsor: **Beth Israel Deaconess Medical Center**

## Conditions studied

- Metastatic Prostate Adenocarcinoma
- Castration-resistant Prostate Cancer
- Prostate Cancer
- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Neratinib

## Key facts

- **NCT ID:** NCT04781374
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-05-21
- **Primary completion:** 2021-09-24
- **Final completion:** 2021-09-24
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawal of funding
- **Last updated:** 2023-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04781374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04781374, "Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04781374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*